Expanding Treatment Options: The Latest Developments in COPD - Episode 12
The MD Magazine Peer Exchange “Expanding Treatment Options: The Latest Developments in COPD Therapy” features a panel of physician experts discussing key topics in COPD therapy, including risk factors, personalized treatment, preventive measures, new combination therapies, and more.
This Peer Exchange is moderated by Peter Salgo, MD, professor of medicine and anesthesiology at Columbia University and an associate director of surgical intensive care at the New York-Presbyterian Hospital in New York City.
The panelists are:
Without head-to-head clinical trial data, it is unknown which type of fixed-dose combination therapy is superior: LABA/corticosteroid or LABA/LAMA. It is also unknown which should be prescribed first, said Hanania, going on to describe scenarios based on phenotype of when each option would be more appropriate.
While triple therapy has been the mainstay of COPD regimens in pulmonologist practices, where the sickest patients are treated, Thomashow acknowledged that they have made a difference to many patients, but that he has made an effort to move away from triple therapy and toward combination LAMA/LABA therapy.